ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report

SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huihui, Song, Tianqi, Xu, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941368/
https://www.ncbi.nlm.nih.gov/pubmed/36824291
http://dx.doi.org/10.1016/j.jtocrr.2023.100464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941368/
https://www.ncbi.nlm.nih.gov/pubmed/36824291
http://dx.doi.org/10.1016/j.jtocrr.2023.100464

Ejemplares similares